ArticleThe pharmacogenomics journal2014
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway.
Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.European archives of psychiatry and clinical neuroscience · 2017Trial
- Neuronal cell adhesion genes and antidepressant response in three independent samples.The pharmacogenomics journal · 2015Trial
- Brain and blood transcriptome profiles delineate common genetic pathways across suicidal ideation and suicide.Molecular psychiatry · 2024Article
- Preclinical models of treatment-resistant depression: challenges and perspectives.Pharmacological reports : PR · 2023Review
- Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment.International clinical psychopharmacology · 2020Review
- Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients.Translational psychiatry · 2020Article
- Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- Pharmacogenetics and Depression: A Critical Perspective.Psychiatry investigation · 2019Article
- The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives.The international journal of neuropsychopharmacology · 2019Review
- Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample.Advances in therapy · 2018Article
- Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis.Translational psychiatry · 2017Article
- Variation in PPP3CC Genotype Is Associated with Long-Term Recovery after Severe Brain Injury.Journal of neurotrauma · 2017Article
- CNV analysis in Chinese children of mental retardation highlights a sex differentiation in parental contribution to de novo and inherited mutational burdens.Scientific reports · 2016Article
- Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway.BMC psychiatry · 2016Article
- Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Current psychiatry reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 5 countries.
Funding
Abstract
Antidepressant pharmacogenetics represents a stimulating, but often discouraging field. The present study proposes a combination of several methodologies across three independent samples. Genes belonging to monoamine, neuroplasticity, circadian rhythm and transcription factor pathways were investigated in two samples (n=369 and 88) with diagnosis of major depression who were treated with antidepressants. Phenotypes were response, remission and treatment-resistant depression. Logistic regression including appropriate covariates was performed. Genes associated with outcomes were investigated in the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) genome-wide study (n=1861). Top genes were further studied through a pathway analysis. In both original samples, markers associated with outcomes were concentrated in the PPP3CC gene. Other interesting findings were particularly in the HTR2A gene in one original sample and the STAR*D. The B-cell receptor signaling pathway proved to be the putative mediator of PPP3CC's effect on antidepressant response (P=0.03). Among innovative candidates, PPP3CC, involved in the regulation of immune system and synaptic plasticity, seems promising for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.